All Stories

  1. Investigation of genetic polymorphisms in pig cytochromes P450 1A2, 2A19, 2C33, 2D25, and 3A22 to elucidate inter-individual variability of hepatic drug oxidations

    Article • Biochemical Pharmacology, December 2025, Elsevier

    Professor Hiroshi Yamazaki

  2. Prediction of Human Hepatic Clearance with HepaSH Monolayers for Low-Turnover Compounds

    Article • Drug Metabolism and Disposition, November 2025, Elsevier

    Professor Hiroshi Yamazaki

  3. Japanese medicinal drug labeling for use in the clinical setting as informed by pharmacogenomic data on cytochrome P450 enzymes obtained from in silico studies

    Article • Drug Metabolism and Pharmacokinetics, October 2025, Elsevier

    Professor Hiroshi Yamazaki

  4. Triethylamine N-oxygenation mediated by liver and kidney microsomes and recombinant flavin-containing monooxygenase 3 (FMO3) and FMO1 proteins from humans, monkeys, pigs, and dogs

    Article • Drug Metabolism and Disposition, September 2025, Elsevier

    Professor Hiroshi Yamazaki

  5. Tyrosine kinase inhibitors, nilotinib and radotinib, suppress both catalytic function and mRNA expression of human cytochrome P450 2J2 and 2C8

    Article • Drug Metabolism and Pharmacokinetics, August 2025, Elsevier

    Professor Hiroshi Yamazaki

  6. Prediction of Internal Exposures after Virtual Oral Doses of Disparate Chemicals in Rats and Humans Using Simplified Physiologically Based Pharmacokinetic Models with In Silico-Generated Input Parameters

    Article • Chemical Research in Toxicology, July 2025, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  7. Investigation of pilocarpine oxidative and hydrolytic metabolism in chimeric mice with humanized liver

    Article • Drug Metabolism and Pharmacokinetics, June 2025, Elsevier

    Professor Hiroshi Yamazaki

  8. Contribution of Japanese scientists to drug metabolism and disposition

    Article • Drug Metabolism and Disposition, May 2025, Elsevier

    Professor Hiroshi Yamazaki

  9. Novel dog hepatic cytochrome P450 3A293 oxidizes endogenous testosterone and estradiol

    Article • Biochemical Pharmacology, May 2025, Elsevier

    Professor Hiroshi Yamazaki

  10. Substrate inhibition potential of arachidonic acid on 14,15-epoxidation, a biological drug developmental target, mediated by recombinant human cytochrome P450 2J2 and 2C8 enzymes

    Article • Drug Metabolism and Pharmacokinetics, April 2025, Elsevier

    Professor Hiroshi Yamazaki

  11. Identification of cytochrome P450 2C18 and 2C76 in tree shrews: P450 2C18 effectively oxidizes typical human P450 2C9/2C19 chiral substrates warfarin and omeprazole with less stereoselectivity

    Article • Biochemical Pharmacology, October 2024, Elsevier

    Professor Hiroshi Yamazaki

  12. Kinetics of the inhibition of CYP3A4 and CYP2C19 activity by jabara juice and identification of the responsible inhibitory components

    Article • Journal of Pharmaceutical Sciences, October 2024, Elsevier

    Professor Hiroshi Yamazaki

  13. Effects of tyrosine kinase inhibitors used for the treatment of non-small cell lung carcinoma on cytochrome P450 2J2 activities

    Article • Xenobiotica, August 2024, Taylor & Francis

    Professor Hiroshi Yamazaki

  14. Investigation of Functional Cytochrome P450 4A Enzymes in Liver and Kidney of Pigs, Cats, Tree Shrews, and Dogs in Comparison with the Metabolic Capacity of Human P450 4A11

    Article • Drug Metabolism and Disposition, July 2024, Elsevier

    Professor Hiroshi Yamazaki

  15. QuinuclidineN-Oxygenation Mediated by Flavin-Containing Monooxygenases 1 and 3 in Kidney and Liver Microsomes from Humans, Monkeys, Dogs, and Pigs

    Article • Drug Metabolism and Disposition, May 2024, Elsevier

    Professor Hiroshi Yamazaki

  16. In Vivo and In Vitro Induction of Cytochrome P450 3A4 by Thalidomide in Humanized-Liver Mice and Experimental Human Hepatocyte HepaSH cells

    Article • Chemical Research in Toxicology, April 2024, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  17. Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources

    Article • Drug Metabolism and Pharmacokinetics, April 2024, Elsevier

    Professor Hiroshi Yamazaki

  18. Transcript abundance of hepatic drug-metabolizing enzymes in two dog breeds compared with 14 species including humans

    Article • Drug Metabolism and Pharmacokinetics, April 2024, Elsevier

    Professor Hiroshi Yamazaki

  19. Novel Tree Shrew Cytochrome P450 2Ds (CYP2D8a and CYP2D8b) Are Functional Drug-Metabolizing Enzymes that Metabolize Bufuralol and Dextromethorphan

    Article • Drug Metabolism and Disposition, January 2024, Elsevier

    Professor Hiroshi Yamazaki

  20. Interaction of a caffeine overdose with clinical doses of contraceptive ethinyl estradiol in a young woman

    Article • Acute Medicine & Surgery, January 2024, Wiley

    Professor Hiroshi Yamazaki

  21. Novel Cytochrome P450 2C119 Enzymes in Cynomolgus and Rhesus Macaques Metabolize Progesterone, Diclofenac, and Omeprazole

    Article • Drug Metabolism and Disposition, December 2023, Elsevier

    Professor Hiroshi Yamazaki

  22. Simple confirmation methods for rare but impaired variants of human flavin-containing monooxygenase 3 (FMO3) found in an updated genome resource databank

    Article • Drug Metabolism and Pharmacokinetics, December 2023, Elsevier

    Professor Hiroshi Yamazaki

  23. Chronic Toxoplasma infection affects gene expression of drug-metabolizing enzymes in mouse liver

    Article • Xenobiotica, November 2023, Taylor & Francis

    Professor Hiroshi Yamazaki

  24. Tree shrew cytochrome P450 2E1 is a functional enzyme that metabolises chlorzoxazone and p -nitrophenol

    Article • Xenobiotica, November 2023, Taylor & Francis

    Professor Hiroshi Yamazaki

  25. A decreasing plasma concentration of a toxicologically active metabolite 9-carboxymethoxymethylguanine after dialysis – A potential new clinical biomarker for improving encephalopathy in patients treated with acyclovir

    Article • Journal of Infection and Chemotherapy, November 2023, Elsevier

    Professor Hiroshi Yamazaki

  26. Pharmacokinetic Models Scaled Up from Humanized Liver Mouse Data Can Account for Drug Monitoring Results of Atomoxetine and Its 4-Hydroxylated andN-Demethylated Metabolites in Pediatric Patients Genotyped for CytochromeP450 2D6

    Article • Drug Metabolism and Disposition, October 2023, Elsevier

    Professor Hiroshi Yamazaki

  27. Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection

    Article • Journal of Pharmaceutical Health Care and Sciences, October 2023, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  28. Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1

    Article • Chemical Research in Toxicology, October 2023, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  29. Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation

    Article • Xenobiotica, July 2023, Taylor & Francis

    Professor Hiroshi Yamazaki

  30. A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria

    Article • Drug Metabolism and Pharmacokinetics, June 2023, Elsevier

    Professor Hiroshi Yamazaki

  31. HepaSH cells: Experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes

    Article • Biochemical and Biophysical Research Communications, June 2023, Elsevier

    Professor Hiroshi Yamazaki

  32. Roles of human cytochrome P450 3A4/5 in dexamethasone 6β-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin

    Article • Drug Metabolism and Pharmacokinetics, June 2023, Elsevier

    Professor Hiroshi Yamazaki

  33. The influence of temperature on the metabolic activity of CYP2C9, CYP2C19, and CYP3A4 genetic variants in vitro

    Article • Xenobiotica, May 2023, Taylor & Francis

    Professor Hiroshi Yamazaki

  34. Variants of Flavin-Containing Monooxygenase 3 Found in Subjects in an Updated Database of Genome Resources

    Article • Drug Metabolism and Disposition, April 2023, Elsevier

    Professor Hiroshi Yamazaki

  35. High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database

    Article • Drug Metabolism and Pharmacokinetics, April 2023, Elsevier

    Professor Hiroshi Yamazaki

  36. Liver microsomal cytochrome P450 3A-dependent drug oxidation activities in individual dogs

    Article • Xenobiotica, March 2023, Taylor & Francis

    Professor Hiroshi Yamazaki

  37. Novel Cytochrome P450 2C94 Functionally Metabolizes Diclofenac and Omeprazole in Dogs

    Article • Drug Metabolism and Disposition, February 2023, Elsevier

    Professor Hiroshi Yamazaki

  38. Newly Identified Tree ShrewCytochrome P4502A13 is Expressed in Liver and Lung and Encodes a Functional Drug-Metabolizing Enzyme Similar to DogCytochrome P4502A13 and PigCytochrome P4502A19

    Article • Drug Metabolism and Disposition, January 2023, Elsevier

    Professor Hiroshi Yamazaki

  39. The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers

    Article • Drug Metabolism and Disposition, January 2023, Elsevier

    Professor Hiroshi Yamazaki

  40. 2-Oxidation, 3-methyl hydroxylation, and 6-hydroxylation of skatole, a contributor to the odour of boar-tainted pork meat, mediated by porcine liver microsomal cytochromes P450 1A2, 2A19, 2E1, and 3A22

    Article • Xenobiotica, January 2023, Taylor & Francis

    Professor Hiroshi Yamazaki

  41. A comprehensive analysis of six forms of cytochrome P450 2C (CYP2C) in pigs

    Article • Xenobiotica, November 2022, Taylor & Francis

    Professor Hiroshi Yamazaki

  42. Further survey of genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found in an updated database of genome resources and identified by phenotyping for trimethylaminuria

    Article • Drug Metabolism and Pharmacokinetics, October 2022, Elsevier

    Professor Hiroshi Yamazaki

  43. Molecular and functional characterization of flavin-containing monooxygenases in pigs, dogs, and cats

    Article • Biochemical Pharmacology, August 2022, Elsevier

    Professor Hiroshi Yamazaki

  44. Correction to “An Updated In Silico Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats”

    Article • Chemical Research in Toxicology, July 2022, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  45. Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2

    Article • Xenobiotica, July 2022, Taylor & Francis

    Professor Hiroshi Yamazaki

  46. Newly identified tree shrew cytochrome P450 2B6 (CYP2B6) and pig CYP2B6b are functional drug-metabolising enzymes

    Article • Xenobiotica, July 2022, Taylor & Francis

    Professor Hiroshi Yamazaki

  47. Plasma and synovial fluid concentrations of linezolid in patients with knee osteoarthritis infected with Staphylococcus aureus

    Article • Journal of Pharmaceutical Health Care and Sciences, July 2022, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  48. A Comprehensive Investigation of Dog Cytochrome P450 3A (CYP3A) Reveals a Functional Role of Newly Identified CYP3A98 in Small Intestine

    Article • Drug Metabolism and Disposition, June 2022, Elsevier

    Professor Hiroshi Yamazaki

  49. Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes

    Article • Drug Metabolism and Disposition, June 2022, Elsevier

    Professor Hiroshi Yamazaki

  50. Molecular and Functional Characterization of N-Acetyltransferases in Common Marmosets and Pigs

    Article • Drug Metabolism and Disposition, June 2022, Elsevier

    Professor Hiroshi Yamazaki

  51. Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies

    Article • Annals of Hematology, June 2022, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  52. Cytochrome P450 2J Genes Are Expressed in Dogs, Cats, and Pigs, and Encode Functional Drug-Metabolizing Enzymes

    Article • Drug Metabolism and Disposition, June 2022, Elsevier

    Professor Hiroshi Yamazaki

  53. Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers

    Article • Drug Metabolism and Pharmacokinetics, June 2022, Elsevier

    Professor Hiroshi Yamazaki

  54. Probe drug T-1032 N-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes in vitro and in humanized-liver mice in vivo

    Article • Drug Metabolism and Pharmacokinetics, June 2022, Elsevier

    Professor Hiroshi Yamazaki

  55. Systematic identification and characterization of cynomolgus macaque solute carrier transporters

    Article • Drug Metabolism and Pharmacokinetics, April 2022, Elsevier

    Professor Hiroshi Yamazaki

  56. Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes

    Article • Xenobiotica, March 2022, Taylor & Francis

    Professor Hiroshi Yamazaki

  57. Plasma Concentration Profiles for Hepatotoxic Pyrrolizidine Alkaloid Senkirkine in Humans Extrapolated from Rat Data Sets Using a Simplified Physiologically Based Pharmacokinetic Model

    Article • Drug Metabolism and Bioanalysis Letters, March 2022, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  58. Oxidation of 3’-methoxyflavone, 4’-methoxyflavone, and 3’,4’-dimethoxyflavone and their derivatives having 5,7-dihydroxyl moieties by human cytochromes P450 1B1 and 2A13

    Article • Xenobiotica, February 2022, Taylor & Francis

    Professor Hiroshi Yamazaki

  59. An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals

    Article • Drug Metabolism and Pharmacokinetics, February 2022, Elsevier

    Professor Hiroshi Yamazaki

  60. Cloning and tissue expression of ATP-binding cassette transporters in cynomolgus macaques

    Article • Drug Metabolism and Pharmacokinetics, February 2022, Elsevier

    Professor Hiroshi Yamazaki

  61. A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects

    Article • Drug Metabolism and Pharmacokinetics, December 2021, Elsevier

    Professor Hiroshi Yamazaki

  62. Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes

    Article • Drug Metabolism and Pharmacokinetics, December 2021, Elsevier

    Professor Hiroshi Yamazaki

  63. Pharmacokinetics of caffeine self-administered in overdose in a Japanese patient admitted to hospital

    Article • Journal of Pharmaceutical Health Care and Sciences, October 2021, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  64. Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes

    Article • Drug Metabolism and Pharmacokinetics, October 2021, Elsevier

    Professor Hiroshi Yamazaki

  65. Prediction of permeability across intestinal cell monolayers for 219 disparate chemicals using in vitro experimental coefficients in a pH gradient system and in silico analyses by trivariate linear regressions and machine learning

    Article • Biochemical Pharmacology, October 2021, Elsevier

    Professor Hiroshi Yamazaki

  66. An Updated In Silico Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats

    Article • Chemical Research in Toxicology, September 2021, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  67. Pharmacokinetics of loxoprofen in a self-administered overdose in a Japanese patient admitted to hospital

    Article • Journal of Pharmaceutical Health Care and Sciences, September 2021, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  68. UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers

    Article • Xenobiotica, September 2021, Taylor & Francis

    Professor Hiroshi Yamazaki

  69. Roles of cytochrome P450 2A6 in the oxidation of flavone, 4′-hydroxyflavone, and 4′-, 3′-, and 2′-methoxyflavones by human liver microsomes

    Article • Xenobiotica, August 2021, Taylor & Francis

    Professor Hiroshi Yamazaki

  70. Pharmacokinetic modeling of over-the-counter drug diphenhydramine self-administered in overdoses in Japanese patients admitted to hospital

    Article • Journal of Pharmaceutical Health Care and Sciences, August 2021, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  71. Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1

    Article • Drug Metabolism and Pharmacokinetics, August 2021, Elsevier

    Professor Hiroshi Yamazaki

  72. Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam

    Article • Drug Metabolism and Pharmacokinetics, August 2021, Elsevier

    Professor Hiroshi Yamazaki

  73. Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: insights into future personalized treatments

    Article • Journal of Pharmaceutical Health Care and Sciences, July 2021, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  74. Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans

    Article • Drug Metabolism and Disposition, June 2021, Elsevier

    Professor Hiroshi Yamazaki

  75. Evaluation of domain of unknown function 1220 (DUF1220) for detection of human genome by quantitative polymerase chain reaction: Potential use in assessing the biodistribution of transplanted therapeutic human cells

    Article • Drug Metabolism and Pharmacokinetics, June 2021, Elsevier

    Professor Hiroshi Yamazaki

  76. Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources

    Article • Drug Metabolism and Pharmacokinetics, June 2021, Elsevier

    Professor Hiroshi Yamazaki

  77. Predicted Contributions of Flavin-containing Monooxygenases to the N-oxygenation of Drug Candidates Based on their Estimated Base Dissociation Constants

    Article • Current Drug Metabolism, April 2021, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  78. Hepatotoxicological potential of P-toluic acid in humanised-liver mice investigated using simplified physiologically based pharmacokinetic models

    Article • Xenobiotica, April 2021, Taylor & Francis

    Professor Hiroshi Yamazaki

  79. In vivo drug interactions of itopride and trimethylamine mediated by flavin-containing monooxygenase 3 in humanized-liver mice

    Article • Drug Metabolism and Pharmacokinetics, April 2021, Elsevier

    Professor Hiroshi Yamazaki

  80. Methyl-hydroxylation and subsequent oxidation to produce carboxylic acid is the major metabolic pathway of tolbutamide in chimeric TK-NOG mice transplanted with human hepatocytes

    Article • Xenobiotica, February 2021, Taylor & Francis

    Professor Hiroshi Yamazaki

  81. Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital

    Article • Journal of Pharmaceutical Health Care and Sciences, February 2021, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  82. Genetic variants of aldehyde oxidase (AOX) 1 in cynomolgus and rhesus macaques

    Article • Xenobiotica, January 2021, Taylor & Francis

    Professor Hiroshi Yamazaki

  83. Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19

    Article • Xenobiotica, January 2021, Taylor & Francis

    Professor Hiroshi Yamazaki

  84. Different Effects of Polymorphic Flavin-Containing Monooxygenase 3 and Cytochrome P450 2A6 Activities on an Index of Arteriosclerosis as a Lifestyle-Related Disease in a General Population in Japan

    Article • Current Drug Metabolism, December 2020, Bentham Science Publishers

    Professor Hiroshi Yamazaki, Dr Kanae Mure

  85. Different Hepatic Concentrations of Bromobenzene, 1,2-Dibromobenzene, and 1,4-Dibromobenzene in Humanized-Liver Mice Predicted Using Simplified Physiologically Based Pharmacokinetic Models as Putative Markers of Toxicological Potential

    Article • Chemical Research in Toxicology, December 2020, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  86. Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling

    Article • Drug Metabolism and Pharmacokinetics, December 2020, Elsevier

    Professor Hiroshi Yamazaki

  87. Trimethylamine N-oxygenation in cynomolgus macaques genotyped for flavin-containing monooxygenase 3 (FMO3)

    Article • Drug Metabolism and Pharmacokinetics, December 2020, Elsevier

    Professor Hiroshi Yamazaki

  88. Plasma and hepatic concentrations of acetaminophen and its primary conjugates after oral administrations determined in experimental animals and humans and extrapolated by pharmacokinetic modeling

    Article • Xenobiotica, November 2020, Taylor & Francis

    Professor Hiroshi Yamazaki

  89. Metabolic Profiles of Tetrabromobisphenol A in Humans Extrapolated from Humanized-Liver Mouse Data Using a Simplified Physiologically Based Pharmacokinetic Model

    Article • Chemical Research in Toxicology, November 2020, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  90. Liquid chromatography-tandem mass spectrometry analysis of oxidation of 2′-, 3′-, 4′- and 6-hydroxyflavanones by human cytochrome P450 enzymes

    Article • Xenobiotica, October 2020, Taylor & Francis

    Professor Hiroshi Yamazaki

  91. Expression of functional sulfotransferases (SULT) 1A1, 1A3, 1B1, 1C2, 1E1, and 2A1 in common marmosets

    Article • Biochemical Pharmacology, October 2020, Elsevier

    Professor Hiroshi Yamazaki

  92. Molecular cloning, sequence analysis, and tissue distribution of marmoset monoamine oxidases A and B

    Article • Drug Metabolism and Pharmacokinetics, October 2020, Elsevier

    Professor Hiroshi Yamazaki

  93. Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital

    Article • Journal of Pharmaceutical Health Care and Sciences, September 2020, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  94. Genetic variants of UDP-glucuronosyltransferases 1A1, 1A6, and 1A9 in cynomolgus and rhesus macaques

    Article • Xenobiotica, August 2020, Taylor & Francis

    Professor Hiroshi Yamazaki

  95. Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1

    Article • Drug Metabolism and Pharmacokinetics, August 2020, Elsevier

    Professor Hiroshi Yamazaki

  96. Molecular characterization of UDP-glucuronosyltransferases 3A and 8A in cynomolgus macaques

    Article • Drug Metabolism and Pharmacokinetics, August 2020, Elsevier

    Professor Hiroshi Yamazaki

  97. Novel variants in outer protein surface of flavin-containing monooxygenase 3 found in an Argentinian case with impaired capacity for trimethylamine N-oxygenation

    Article • Drug Metabolism and Pharmacokinetics, August 2020, Elsevier

    Professor Hiroshi Yamazaki

  98. Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data

    Article • Drug Metabolism and Pharmacokinetics, August 2020, Elsevier

    Professor Hiroshi Yamazaki

  99. Regional distributions of UDP-glucuronosyltransferase activities toward estradiol and serotonin in the liver and small intestine of cynomolgus macaques

    Article • Drug Metabolism and Pharmacokinetics, August 2020, Elsevier

    Professor Hiroshi Yamazaki

  100. Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations

    Article • Xenobiotica, July 2020, Taylor & Francis

    Professor Hiroshi Yamazaki

  101. Genetic variants of N-acetyltransferases 1 and 2 (NAT1 and NAT2) in cynomolgus and rhesus macaques

    Article • Biochemical Pharmacology, July 2020, Elsevier

    Professor Hiroshi Yamazaki

  102. Interleukin-1β and tumor necrosis factor-α affect cytochrome P450 expression in cynomolgus macaque hepatocytes

    Article • Drug Metabolism and Pharmacokinetics, June 2020, Elsevier

    Professor Hiroshi Yamazaki

  103. Human Aldehyde Oxidase 1-mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes

    Article • Drug Metabolism and Disposition, May 2020, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  104. Preference forO-demethylation reactions in the oxidation of 2′-, 3′-, and 4′-methoxyflavones by human cytochrome P450 enzymes

    Article • Xenobiotica, April 2020, Taylor & Francis

    Professor Hiroshi Yamazaki

  105. Systematic characterization of glutathione S-transferases in common marmosets

    Article • Biochemical Pharmacology, April 2020, Elsevier

    Professor Hiroshi Yamazaki

  106. Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment

    Article • Xenobiotica, January 2020, Taylor & Francis

    Professor Hiroshi Yamazaki

  107. Metabolic profiles of coumarin in human plasma extrapolated from a rat data set with a simplified physiologically based pharmacokinetic model

    Article • The Journal of Toxicological Sciences, January 2020, Japanese Society of Toxicology

    Professor Hiroshi Yamazaki

  108. The marmoset cytochrome P450 superfamily: Sequence/phylogenetic analyses, genomic structure, and catalytic function

    Article • Biochemical Pharmacology, January 2020, Elsevier

    Professor Hiroshi Yamazaki

  109. Different Roles of Human Cytochrome P450 2C9 and 3A Enzymes in Diclofenac 4′- and 5-Hydroxylations Mediated by Metabolically Inactivated Human Hepatocytes in Previously Transplanted Chimeric Mice

    Article • Chemical Research in Toxicology, December 2019, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  110. Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver

    Article • Xenobiotica, November 2019, Taylor & Francis

    Professor Hiroshi Yamazaki

  111. Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes

    Article • Xenobiotica, November 2019, Taylor & Francis

    Professor Hiroshi Yamazaki

  112. Expression levels of microRNAs that are potential cytochrome P450 regulators in cynomolgus macaques

    Article • Xenobiotica, November 2019, Taylor & Francis

    Professor Hiroshi Yamazaki

  113. Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling

    Article • Biopharmaceutics & Drug Disposition, November 2019, Wiley

    Professor Hiroshi Yamazaki

  114. Predicting successful/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver

    Article • Xenobiotica, September 2019, Taylor & Francis

    Professor Hiroshi Yamazaki

  115. Molecular and functional characterization of cytosolic sulfotransferases in cynomolgus macaque

    Article • Biochemical Pharmacology, August 2019, Elsevier

    Professor Hiroshi Yamazaki

  116. Functional and molecular characterization of UDP-glucuronosyltransferase 2 family in cynomolgus macaques

    Article • Biochemical Pharmacology, May 2019, Elsevier

    Professor Hiroshi Yamazaki

  117. Survey of Drug Oxidation Activities in Hepatic and Intestinal Microsomes of Individual Common Marmosets, a New Nonhuman Primate Animal Model

    Article • Current Drug Metabolism, April 2019, Bentham Science Publishers

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  118. Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes

    Article • Chemical Research in Toxicology, April 2019, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  119. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes

    Article • Biopharmaceutics & Drug Disposition, February 2019, Wiley

    Professor Hiroshi Yamazaki

  120. Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques

    Article • Drug Metabolism and Pharmacokinetics, February 2019, Elsevier

    Professor Hiroshi Yamazaki

  121. Steady-State Human Pharmacokinetics of Monobutyl Phthalate Predicted by Physiologically Based Pharmacokinetic Modeling Using Single-Dose Data from Humanized-Liver Mice Orally Administered with Dibutyl Phthalate

    Article • Chemical Research in Toxicology, January 2019, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  122. Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator‐activated receptor‐alpha modulator, in rats and monkeys

    Article • Biopharmaceutics & Drug Disposition, January 2019, Wiley

    Professor Hiroshi Yamazaki

  123. Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6

    Article • Xenobiotica, December 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  124. Predictability of human pharmacokinetics of diisononyl phthalate (DINP) using chimeric mice with humanized liver

    Article • Xenobiotica, December 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  125. Plasma and Hepatic Concentrations of Chemicals after Virtual Oral Administrations Extrapolated Using Rat Plasma Data and Simple Physiologically Based Pharmacokinetic Models

    Article • Chemical Research in Toxicology, December 2018, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  126. Novel variants and haplotypes of human flavin-containing monooxygenase 3 gene associated with Japanese subjects suffering from trimethylaminuria

    Article • Xenobiotica, November 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  127. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals

    Article • Drug Metabolism and Disposition, November 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  128. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques

    Article • Chemical Research in Toxicology, November 2018, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  129. Molecular and Functional Characterization of N-Acetyltransferases NAT1 and NAT2 in Cynomolgus Macaque

    Article • Chemical Research in Toxicology, October 2018, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  130. In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions

    Article • Xenobiotica, September 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  131. Expression and metabolic activity of flavin-containing monooxygenase 1 in cynomolgus macaque kidney

    Article • Journal of Medical Primatology, September 2018, Wiley

    Professor Hiroshi Yamazaki

  132. In vivo hepatic clearance of lipophilic drugs predicted by in vitro uptake data into cryopreserved hepatocytes suspended in sera of rats, guinea pigs, monkeys and humans

    Article • Xenobiotica, September 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  133. Functionally relevant genetic variants of glutathione S-transferase GSTM5 in cynomolgus and rhesus macaques

    Article • Xenobiotica, September 2018, Taylor & Francis

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  134. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital

    Article • Xenobiotica, September 2018, Taylor & Francis

    Professor Hiroshi Yamazaki, Minoru Kogiku

  135. Genetic Variants of Glutathione S-Transferase GSTT1 and GSTT2 in Cynomolgus Macaques: Identification of GSTT Substrates and Functionally Relevant Alleles

    Article • Chemical Research in Toxicology, August 2018, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  136. Oxidation of flavanone and flavone by cytochrome P450 2A6

    Article • Xenobiotica, July 2018, Taylor & Francis

    Haruna Nagayoshi, Professor Hiroshi Yamazaki

  137. Expression and inducibility of cytochrome P450s in human hepatocytes isolated from chimeric mice with humanized livers

    Article • Xenobiotica, July 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  138. Suitable albumin concentrations for enhanced drug oxidation activities mediated by human liver microsomal cytochrome P450 2C9 and other forms predicted with unbound fractions and partition/distribution coefficients of model substrates

    Article • Xenobiotica, June 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  139. Human urinary concentrations of monoisononyl phthalate estimated using physiologically based pharmacokinetic modeling and experimental pharmacokinetics in humanized-liver mice orally administered with diisononyl phthalate

    Article • Xenobiotica, May 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  140. Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver

    Article • Xenobiotica, April 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  141. Chimeric mice with humanized liver as a model for testing organophosphate and carbamate pesticide exposure

    Article • Pest Management Science, February 2018, Wiley

    Professor Hiroshi Yamazaki

  142. Polymorphisms of cytochrome P450 2B6 (CYP2B6 ) in cynomolgus and rhesus macaques

    Article • Journal of Medical Primatology, February 2018, Wiley

    Professor Hiroshi Yamazaki

  143. Marmoset cytochrome P450 2B6, a propofol hydroxylase expressed in liver

    Article • Xenobiotica, February 2018, Taylor & Francis

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  144. Improved Intranasal Retentivity and Transnasal Absorption Enhancement by PEGylated Poly-l-ornithine

    Article • Pharmaceuticals, January 2018, MDPI AG

    Professor Hiroshi Yamazaki

  145. Cytochrome P450 2A6 and Other Human P450 Enzymes in the Oxidation of Flavone and Flavanone

    Article • Xenobiotica, January 2018, Taylor & Francis

    Professor Hiroshi Yamazaki

  146. Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies

    Article • Biopharmaceutics & Drug Disposition, December 2017, Wiley

    Professor Hiroshi Yamazaki

  147. Molecular cloning and tissue distribution of a novel marmoset ABC transporter

    Article • Biopharmaceutics & Drug Disposition, December 2017, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  148. The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage

    Article • Chemical Research in Toxicology, August 2017, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki, Professor Norio Shibata

  149. Development of genotyping method for functionally relevant variants of cytochromes P450 in cynomolgus macaques

    Article • Journal of Veterinary Pharmacology and Therapeutics, July 2017, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  150. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19

    Article • Xenobiotica, July 2017, Taylor & Francis

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  151. Marmoset pulmonary cytochrome P450 2F1 oxidizes biphenyl and 7-ethoxycoumarin and hepatic human P450 substrates

    Article • Xenobiotica, July 2017, Taylor & Francis

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  152. Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants

    Article • Xenobiotica, July 2017, Taylor & Francis

    Professor Hiroshi Yamazaki

  153. Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models

    Article • Biopharmaceutics & Drug Disposition, July 2017, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  154. Hepatic expression of cytochrome P450 enzymes in non-human primate species

    Article • Journal of Medical Primatology, June 2017, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  155. Functional characterization and tissue expression of marmoset cytochrome P450 2E1

    Article • Biopharmaceutics & Drug Disposition, June 2017, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  156. Terfenadine t-butyl hydroxylation catalyzed by human and marmoset cytochrome P450 3A and 4F enzymes in livers and small intestines

    Article • Xenobiotica, May 2017, Taylor & Francis

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  157. Regio- and Stereo-Selective Oxidation of a Cardiovascular Drug, Metoprolol, Mediated by Cytochrome P450 2D and 3A Enzymes in Marmoset Livers

    Article • Drug Metabolism and Disposition, May 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  158. Molecular Cloning and Characterization of Marmoset Aldehyde Oxidase

    Article • Drug Metabolism and Disposition, May 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  159. Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects

    Article • International Journal of Food Sciences and Nutrition, April 2017, Taylor & Francis

    Professor Hiroshi Yamazaki

  160. Marmoset Flavin-Containing Monooxygenase 3 in the Liver Is a Major Benzydamine and Sulindac Sulfide Oxygenase

    Article • Drug Metabolism and Disposition, March 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  161. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone

    Article • Drug Metabolism and Disposition, February 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  162. A Case of Delayed Emergence After Propofol Anesthesia

    Article • A & A Case Reports, December 2016, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  163. Utility of non-human primates in drug development: Comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes

    Article • Biochemical Pharmacology, December 2016, Elsevier

    Professor Hiroshi Yamazaki

  164. Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice

    Article • Xenobiotica, November 2016, Taylor & Francis

    Professor Hiroshi Yamazaki

  165. Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets

    Article • Biochemical Pharmacology, November 2016, Elsevier

    Professor Hiroshi Yamazaki

  166. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes

    Article • Chemical Research in Toxicology, October 2016, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  167. Pre-incubation with cyclosporine A potentiates its inhibitory effects on pitavastatin uptake mediated by recombinantly expressed cynomolgus monkey hepatic organic anion transporting polypeptide

    Article • Biopharmaceutics & Drug Disposition, October 2016, Wiley

    Yasuhiro Uno, Professor Hiroshi Yamazaki

  168. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules

    Article • Biopharmaceutics & Drug Disposition, September 2016, Wiley

    Professor Hiroshi Yamazaki

  169. Roles of Human CYP2A6 and Monkey CYP2A24 and 2A26 Cytochrome P450 Enzymes in the Oxidation of 2,5,2′,5′-Tetrachlorobiphenyl

    Article • Drug Metabolism and Disposition, September 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  170. In vivoindividual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9

    Article • Biopharmaceutics & Drug Disposition, September 2016, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  171. Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry

    Article • Chemical Research in Toxicology, July 2016, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki, Professor Norio Shibata

  172. Systematic approach to optimize a pretreatment method for ultrasensitive liquid chromatography with tandem mass spectrometry analysis of multiple target compounds in biological samples

    Article • Journal of Separation Science, July 2016, Wiley

    Professor Hiroshi Yamazaki

  173. Marmoset cytochrome P450 4A11, a novel arachidonic acid and lauric acid ω-hydroxylase expressed in liver and kidney tissues

    Article • Xenobiotica, July 2016, Taylor & Francis

    Professor Hiroshi Yamazaki

  174. Simulation of human plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling

    Article • Xenobiotica, July 2016, Taylor & Francis

    Professor Hiroshi Yamazaki

  175. Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology

    Article • Chemical Research in Toxicology, July 2016, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  176. Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors

    Article • Biopharmaceutics & Drug Disposition, July 2016, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  177. Structure–Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6

    Article • Chemical Research in Toxicology, May 2016, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  178. Analysis of gene expression for microminipig liver transcriptomes using parallel long-read technology and short-read sequencing

    Article • Biopharmaceutics & Drug Disposition, May 2016, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  179. Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population

    Article • Gastroenterology, May 2016, Elsevier

    Professor Hiroshi Yamazaki

  180. Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers

    Article • Drug Metabolism and Disposition, April 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  181. A New Marmoset P450 4F12 Enzyme Expressed in Small Intestines and Livers Efficiently Metabolizes Antihistaminic Drug Ebastine

    Article • Drug Metabolism and Disposition, April 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  182. Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling

    Article • Xenobiotica, February 2016, Taylor & Francis

    Professor Hiroshi Yamazaki

  183. Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model

    Article • Scientific Reports, February 2016, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  184. Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine

    Article • Xenobiotica, February 2016, Taylor & Francis

    Professor Hiroshi Yamazaki

  185. Individual differences inin vitroandin vivometabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3

    Article • Human Psychopharmacology Clinical and Experimental, February 2016, Wiley

    Professor Hiroshi Yamazaki

  186. Individual differences inin vitroandin vivometabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5

    Article • Human Psychopharmacology Clinical and Experimental, February 2016, Wiley

    Professor Hiroshi Yamazaki

  187. Functional polymer‐dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes

    Article • Hepatology Research, February 2016, Wiley

    Professor Hiroshi Yamazaki

  188. In vitroinhibition and enhancement of liver microsomal S-777469 metabolism by long-chain fatty acids and serum albumin: insight intoin vitroandin vivodiscrepancy of metabolite formation in humans

    Article • Xenobiotica, December 2015, Taylor & Francis

    Professor Hiroshi Yamazaki

  189. Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling

    Article • Xenobiotica, December 2015, Taylor & Francis

    Professor Hiroshi Yamazaki

  190. Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances

    Article • Biopharmaceutics & Drug Disposition, December 2015, Wiley

    Professor Hiroshi Yamazaki, Yasuhiro Uno

  191. Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria

    Article • Molecular Genetics and Metabolism Reports, December 2015, Elsevier

    Professor Hiroshi Yamazaki

  192. Dataset for genotyping validation of cytochrome P450 2A6 whole-gene deletion ( CYP2A6 * 4 ) by real-time polymerase chain reaction platforms

    Article • Data in Brief, December 2015, Elsevier

    Professor Hiroshi Yamazaki

  193. Molecular Cloning, Tissue Distribution, and Functional Characterization of Marmoset Cytochrome P450 1A1, 1A2, and 1B1

    Article • Drug Metabolism and Disposition, October 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  194. Point mutation of cytochrome P450 2A6 (a polymorphic variant CYP2A6.25) confers new substrate specificity towards flavonoids

    Article • Biopharmaceutics & Drug Disposition, August 2015, Wiley

    Professor Hiroshi Yamazaki

  195. Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13

    Article • Xenobiotica, August 2015, Taylor & Francis

    Professor Hiroshi Yamazaki

  196. Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates,S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole

    Article • Drug Metabolism and Disposition, July 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  197. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus)

    Article • Xenobiotica, June 2015, Taylor & Francis

    Professor Hiroshi Yamazaki

  198. Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays

    Article • Drug Metabolism Letters, June 2015, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  199. Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling

    Article • Xenobiotica, June 2015, Taylor & Francis

    Professor Hiroshi Yamazaki

  200. Human urine and plasma concentrations of bisphenol A extrapolated from pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and semi-physiological pharmacokinetic modeling

    Article • Regulatory Toxicology and Pharmacology, June 2015, Elsevier

    Professor Hiroshi Yamazaki

  201. Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase

    Article • Drug Metabolism and Disposition, May 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  202. Human biofluid concentrations of mono(2-ethylhexyl)phthalate extrapolated from pharmacokinetics in chimeric mice with humanized liver administered with di(2-ethylhexyl)phthalate and physiologically based pharmacokinetic modeling

    Article • Environmental Toxicology and Pharmacology, May 2015, Elsevier

    Professor Hiroshi Yamazaki

  203. Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo

    Article • Biochemical Pharmacology, May 2015, Elsevier

    Professor Hiroshi Yamazaki

  204. Substrate Selectivities and Catalytic Activities of Marmoset Liver Cytochrome P450 2A6 Differed from Those of Human P450 2A6

    Article • Drug Metabolism and Disposition, April 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  205. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan

    Article • Xenobiotica, March 2015, Taylor & Francis

    Professor Hiroshi Yamazaki

  206. Activation and Deactivation of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine by Cytochrome P450 Enzymes and Flavin-Containing Monooxygenases in Common Marmosets (Callithrix jacchus)

    Article • Drug Metabolism and Disposition, March 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  207. Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients

    Article • Journal of Cardiovascular Pharmacology, March 2015, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  208. CYP2D44 polymorphisms in cynomolgus and rhesus macaques

    Article • Molecular Biology Reports, February 2015, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  209. Regioselective hydroxylation of steroid hormones by human cytochromes P450

    Article • Drug Metabolism Reviews, February 2015, Taylor & Francis

    Professor Hiroshi Yamazaki

  210. Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes

    Article • Chemical Research in Toxicology, February 2015, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  211. Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans

    Article • Drug Metabolism and Pharmacokinetics, February 2015, Elsevier

    Professor Hiroshi Yamazaki

  212. Genetic polymorphism of cynomolgus and rhesus macaque CYP2C9

    Article • Drug Metabolism and Pharmacokinetics, February 2015, Elsevier

    Professor Hiroshi Yamazaki

  213. Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes

    Article • Clinica Chimica Acta, February 2015, Elsevier

    Professor Hiroshi Yamazaki

  214. Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers

    Article • Drug Metabolism and Pharmacokinetics, February 2015, Elsevier

    Professor Hiroshi Yamazaki

  215. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling

    Article • Biopharmaceutics & Drug Disposition, January 2015, Wiley

    Professor Hiroshi Yamazaki

  216. Zone analysis by two-dimensional electrophoresis with accelerator mass spectrometry of in vivo protein bindings of idiosyncratic hepatotoxicants troglitazone and flutamide bioactivated in chimeric mice with humanized liver

    Article • Toxicology Research, January 2015, Oxford University Press (OUP)

    Professor Hiroshi Yamazaki

  217. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients

    Article • Biochemical Pharmacology, January 2015, Elsevier

    Professor Hiroshi Yamazaki

  218. Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations

    Article • The Journal of Toxicological Sciences, January 2015, Japanese Society of Toxicology

    Professor Hiroshi Yamazaki

  219. Intravenous Administration of Apomorphine Does NOT Induce Long QT Syndrome: Experimental Evidence fromIn VivoCanine Models

    Article • Basic & Clinical Pharmacology & Toxicology, November 2014, Wiley

    Professor Hiroshi Yamazaki

  220. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam andR-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys usingin vitro–in vivocorrelation

    Article • Xenobiotica, November 2014, Taylor & Francis

    Professor Hiroshi Yamazaki

  221. Pharmacokinetics and effects on serum cholinesterase activities of organophosphorus pesticides acephate and chlorpyrifos in chimeric mice transplanted with human hepatocytes

    Article • Regulatory Toxicology and Pharmacology, November 2014, Elsevier

    Professor Hiroshi Yamazaki

  222. Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes

    Article • Cardiovascular Toxicology, October 2014, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  223. Evaluation of 89 Compounds for Identification of Substrates for Cynomolgus Monkey CYP2C76, a New Bupropion/Nifedipine Oxidase

    Article • Drug Metabolism and Disposition, October 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  224. Human plasma concentrations of herbicidal carbamate molinate extrapolated from the pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and physiologically based pharmacokinetic modeling

    Article • Regulatory Toxicology and Pharmacology, October 2014, Elsevier

    Professor Hiroshi Yamazaki

  225. CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques

    Article • Biochemical Pharmacology, September 2014, Elsevier

    Professor Hiroshi Yamazaki

  226. Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine

    Article • Xenobiotica, August 2014, Taylor & Francis

    Professor Hiroshi Yamazaki

  227. Polymorphisms of CYP2D17 in Cynomolgus and Rhesus Macaques: an Evidence of the Genetic Basis for the Variability of CYP2D-Dependent Drug Metabolism

    Article • Drug Metabolism and Disposition, July 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  228. Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs

    Article • Biochemical Pharmacology, July 2014, Elsevier

    Professor Hiroshi Yamazaki

  229. Qualitative De Novo Analysis of Full Length cDNA and Quantitative Analysis of Gene Expression for Common Marmoset (Callithrix jacchus) Transcriptomes Using Parallel Long-Read Technology and Short-Read Sequencing

    Article • PLOS One, June 2014, PLOS

    Professor Hiroshi Yamazaki

  230. Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig

    Article • Biopharmaceutics & Drug Disposition, May 2014, Wiley

    Professor Hiroshi Yamazaki

  231. Trimethylamine generation in patients receiving hemodialysis treated with L-carnitine

    Article • Clinical Kidney Journal, May 2014, Oxford University Press (OUP)

    Professor Hiroshi Yamazaki

  232. Effect of Ketoconazole on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: An Open-Label Study in Healthy White Subjects in Germany

    Article • Clinical Therapeutics, May 2014, Elsevier

    Professor Hiroshi Yamazaki

  233. Relationships between flavin‐containing mono‐oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population

    Article • British Journal of Clinical Pharmacology, April 2014, Wiley

    Professor Hiroshi Yamazaki

  234. Age-related pharmacokinetic changes of acetaminophen, antipyrine, diazepam, diphenhydramine, and ofloxacin in male cynomolgus monkeys and beagle dogs

    Article • Xenobiotica, March 2014, Taylor & Francis

    Professor Hiroshi Yamazaki

  235. Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys

    Article • Xenobiotica, March 2014, Taylor & Francis

    Professor Hiroshi Yamazaki

  236. Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450

    Article • Drug Metabolism and Disposition, February 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  237. Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of the Pregnane X Receptor

    Article • Chemical Research in Toxicology, February 2014, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki, Professor Norio Shibata

  238. Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype

    Article • The Journal of Infectious Diseases, January 2014, Oxford University Press (OUP)

    Professor Hiroshi Yamazaki

  239. Drug-induced Liver Toxicity Studies: Research into Human Metabolites Clarifies Their Role in Drug Development

    Article • Drug Metabolism and Pharmacokinetics, January 2014, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  240. Comparison of Catalytic Properties of Cytochromes P450 3A4 and 3A5 by Molecular Docking Simulation

    Article • Drug Metabolism Letters, December 2013, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  241. Human Cytochrome P450 Oxidation of 5-Hydroxythalidomide and Pomalidomide, an Amino Analogue of Thalidomide

    Article • Chemical Research in Toxicology, December 2013, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki, Professor Norio Shibata

  242. The human hepatic cell line HepaRG as a possible cell source for the generation of humanized liver TK-NOG mice

    Article • Xenobiotica, September 2013, Taylor & Francis

    Professor Hiroshi Yamazaki

  243. Systematic identification and characterization of glutathione S-transferases in cynomolgus macaque

    Article • Biochemical Pharmacology, September 2013, Elsevier

    Professor Hiroshi Yamazaki

  244. Pitavastatin as an In Vivo Probe for Studying Hepatic Organic Anion Transporting Polypeptide-Mediated Drug–Drug Interactions in Cynomolgus Monkeys

    Article • Drug Metabolism and Disposition, August 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  245. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

    Article • Xenobiotica, July 2013, Taylor & Francis

    Professor Hiroshi Yamazaki

  246. Characterization of Microsomal Glutathione S-Transferases MGST1, MGST2, and MGST3 in Cynomolgus Macaque

    Article • Drug Metabolism and Disposition, June 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  247. Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation

    Article • Xenobiotica, June 2013, Taylor & Francis

    Professor Hiroshi Yamazaki

  248. Molecular and functional characterization of flavin-containing monooxygenases in cynomolgus macaque

    Article • Biochemical Pharmacology, June 2013, Elsevier

    Professor Hiroshi Yamazaki

  249. Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities

    Article • Biochemical Pharmacology, June 2013, Elsevier

    Professor Hiroshi Yamazaki

  250. Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline

    Article • Xenobiotica, May 2013, Taylor & Francis

    Professor Hiroshi Yamazaki

  251. Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling

    Article • Regulatory Toxicology and Pharmacology, April 2013, Elsevier

    Professor Hiroshi Yamazaki

  252. Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition

    Article • Chemical Research in Toxicology, March 2013, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  253. Metabolic Activation of Polycyclic Aromatic Hydrocarbons and Aryl and Heterocyclic Amines by Human Cytochromes P450 2A13 and 2A6

    Article • Chemical Research in Toxicology, March 2013, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  254. In Vivo Drug Interactions of the Teratogen Thalidomide with Midazolam: Heterotropic Cooperativity of Human Cytochrome P450 in Humanized TK-NOG Mice

    Article • Chemical Research in Toxicology, March 2013, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki, Professor Norio Shibata

  255. Cardiohemodynamic and Electrophysiological Effects of Anti-influenza Drug Oseltamivir In Vivo and In Vitro

    Article • Cardiovascular Toxicology, February 2013, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  256. Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy

    Article • Drug Metabolism and Pharmacokinetics, January 2013, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  257. Cytochrome P450 Metabolic Activities in the Small Intestine of Cynomolgus Macaques Bred in Cambodia, China, and Indonesia

    Article • Drug Metabolism and Pharmacokinetics, January 2013, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  258. Drug Interactions Mediated by Drug-Metabolizing Enzymes

    Article • Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, January 2013, Japanese Society of Clinical Pharmacology and Therapeutics

    Professor Hiroshi Yamazaki

  259. Mechanism-based Inhibition of CYP1A1 and CYP3A4 by the Furanocoumarin Chalepensin

    Article • Drug Metabolism and Pharmacokinetics, January 2013, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  260. The <i>CYP3A4</i> intron 6 C>T polymorphism (<i>CYP3A4*22</i>) is associated with reduced CYP3A4 protein level and function in human liver microsomes

    Article • The Journal of Toxicological Sciences, January 2013, Japanese Society of Toxicology

    Professor Hiroshi Yamazaki

  261. Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation

    Article • Biochemical Pharmacology, December 2012, Elsevier

    Professor Hiroshi Yamazaki

  262. Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population

    Article • Molecular Genetics and Metabolism, November 2012, Elsevier

    Professor Hiroshi Yamazaki

  263. Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis

    Article • Thrombosis Research, October 2012, Elsevier

    Professor Hiroshi Yamazaki

  264. A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole-gene deletion allele from 2D6*10 alleles

    Article • Clinica Chimica Acta, October 2012, Elsevier

    Professor Hiroshi Yamazaki

  265. Comparison of Cytochrome P450 2C Subfamily Members in Terms of Drug Oxidation Rates and Substrate Inhibition

    Article • Current Drug Metabolism, September 2012, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  266. Note to readers

    Article • Biochemical Pharmacology, August 2012, Elsevier

    Professor Hiroshi Yamazaki

  267. Cytochrome P450 2A6 Phenotyping Based on Dietary Caffeine Intake in a Japanese Population of Non-smokers

    Article • Drug Metabolism Letters, June 2012, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  268. In Vivo Formation of Dihydroxylated and Glutathione Conjugate Metabolites Derived from Thalidomide and 5-Hydroxythalidomide in Humanized TK-NOG Mice

    Article • Chemical Research in Toxicology, January 2012, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki, Professor Norio Shibata

  269. CYP2C76 Non-synonymous Variants in Cynomolgus and Rhesus Macaques

    Article • Drug Metabolism and Pharmacokinetics, January 2012, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  270. Expression Profile of Hepatic Genes in Cynomolgus Macaques Bred in Cambodia, China, and Indonesia: Implications for Cytochrome P450 Genes

    Article • Drug Metabolism and Pharmacokinetics, January 2012, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  271. Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs

    Article • The Journal of Toxicological Sciences, January 2012, Japanese Society of Toxicology

    Professor Hiroshi Yamazaki

  272. Different Metabolites of Human Hepatotoxic Pyrazolopyrimidine Derivative 5‐n‐Butyl‐Pyrazolo[1,5‐a]Pyrimidine Produced by Human, Rat and Monkey Cytochrome P450 1A2 and Liver Microsomes

    Article • Basic & Clinical Pharmacology & Toxicology, November 2011, Wiley

    Professor Hiroshi Yamazaki

  273. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients

    Article • Journal of Clinical Pharmacy and Therapeutics, August 2011, Hindawi Publishing Corporation

    Professor Hiroshi Yamazaki

  274. Immunochemical Detection of Cytochrome P450 Enzymes in Liver Microsomes of 27 Cynomolgus Monkeys

    Article • Journal of Pharmacology and Experimental Therapeutics, August 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  275. Human Liver Enzymes Responsible for Metabolic Elimination of Tyramine, a Vasopressor Agent from Daily Food

    Article • Drug Metabolism Letters, August 2011, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  276. Spectral Modification and Catalytic Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by Four Chemopreventive Organoselenium Compounds

    Article • Chemical Research in Toxicology, July 2011, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  277. Metabolism of P450 Probe Substrates by Cynomolgus Monkey CYP2C76

    Article • Basic & Clinical Pharmacology & Toxicology, July 2011, Wiley

    Professor Hiroshi Yamazaki

  278. Mechanism‐based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo

    Article • Bone Marrow Transplantation, June 2011, Wiley

    Professor Hiroshi Yamazaki

  279. Comparison of Cytochrome P450 2D6 and Variants in Terms of Drug Oxidation Rates and Substrate Inhibition

    Article • Current Drug Metabolism, June 2011, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  280. Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method

    Article • Clinica Chimica Acta, June 2011, Elsevier

    Professor Hiroshi Yamazaki

  281. Two Naturally Occurring Terpenes, Dehydrocostuslactone and Costunolide, Decrease Intracellular GSH Content and Inhibit STAT3 Activation

    Article • PLOS One, May 2011, PLOS

    Professor Hiroshi Yamazaki

  282. Developmental variations in metabolic capacity of flavin‐containing mono‐oxygenase 3 in childhood

    Article • British Journal of Clinical Pharmacology, March 2011, Wiley

    Professor Hiroshi Yamazaki

  283. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function

    Article • Drug Metabolism Reviews, February 2011, Taylor & Francis

    Professor Hiroshi Yamazaki

  284. Newly Identified CYP2C93 Is a Functional Enzyme in Rhesus Monkey, but Not in Cynomolgus Monkey

    Article • PLOS One, February 2011, PLOS

    Professor Hiroshi Yamazaki

  285. In Vivo Formation of a Glutathione Conjugate Derived from Thalidomide in Humanized uPA-NOG Mice

    Article • Chemical Research in Toxicology, February 2011, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki, Professor Norio Shibata

  286. CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey

    Article • Biochemical Pharmacology, February 2011, Elsevier

    Professor Hiroshi Yamazaki

  287. Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1′-Hydroxylation

    Article • Drug Metabolism and Disposition, January 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  288. Comparison of the Inhibitory Profiles of Itraconazole and Cimetidine in Cytochrome P450 3A4 Genetic Variants

    Article • Drug Metabolism and Disposition, January 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  289. A Newly Developed DNA Microarray Is Useful to Assess Induction of Cytochromes P450 in the Cynomolgus Monkey

    Article • Drug Metabolism and Pharmacokinetics, January 2011, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  290. CYP1B1 is Polymorphic in Cynomolgus and Rhesus Macaques

    Article • Journal of Veterinary Medical Science, January 2011, Japanese Society of Veterinary Science

    Professor Hiroshi Yamazaki

  291. Cynomolgus Macaque CYP4 Isoforms Are Functional,Metabolizing Arachidonic Acid

    Article • Journal of Veterinary Medical Science, January 2011, Japanese Society of Veterinary Science

    Professor Hiroshi Yamazaki

  292. Discovery of Genetic Variants in CYP1D1: Implication for Functional Integrity of CYP1D1 in Cynomolgus Macaques and Rhesus Macaques

    Article • Drug Metabolism and Pharmacokinetics, January 2011, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  293. Drug Metabolism and Toxicity in Chimeric Mice with Humanized Liver

    Article • JOURNAL OF HEALTH SCIENCE, January 2011, Pharmaceutical Society of Japan

    Professor Hiroshi Yamazaki

  294. Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system

    Article • Journal of Bioscience and Bioengineering, January 2011, Elsevier

    Professor Hiroshi Yamazaki

  295. Expression of Cytochromes P450 in Fetal, Infant, and Juvenile Liver of Cynomolgus Macaques

    Article • Drug Metabolism and Pharmacokinetics, January 2011, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  296. Human Cytochrome P450 1A1 Is a Novel Target Gene of Liver X Receptor α

    Article • Drug Metabolism and Pharmacokinetics, January 2011, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  297. Individual Differences in Pharmacokinetics and Pharmacodynamics of Anesthetic Agent Propofol with Regard to CYP2B6 and UGT1A9 Genotype and Patient Age

    Article • Drug Metabolism and Pharmacokinetics, January 2011, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  298. Microminipig, a Non-rodent Experimental Animal Optimized for Life Science Research: In Vivo Proarrhythmia Models of Drug-Induced Long QT Syndrome: Development of Chronic Atrioventricular Block Model of Microminipig

    Article • Journal of Pharmacological Sciences, January 2011, Japanese Pharmacological Society

    Professor Hiroshi Yamazaki

  299. Species Difference between Cynomolgus Monkeys and Humans on Cytochromes P450 2D and 3A-Dependent Drug Oxidation Activities in Liver Microsomes

    Article • JOURNAL OF HEALTH SCIENCE, January 2011, Pharmaceutical Society of Japan

    Professor Hiroshi Yamazaki

  300. CYP2G2, Pseudogenized in Human, Is Expressed in Nasal Mucosa of Cynomolgus Monkey and Encodes a Functional Drug-Metabolizing Enzyme

    Article • Drug Metabolism and Disposition, December 2010, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  301. Structure−Function Relationships of Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 Flavonoid Derivatives

    Article • Chemical Research in Toxicology, November 2010, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  302. Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling

    Article • Regulatory Toxicology and Pharmacology, November 2010, Elsevier

    Professor Hiroshi Yamazaki

  303. Methodologies for Investigating Drug Metabolism at the Early Drug Discovery Stage: Prediction of Hepatic Drug Clearance and P450 Contribution

    Article • Current Drug Metabolism, October 2010, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  304. Human Blood Concentrations of Cotinine, a Biomonitoring Marker for Tobacco Smoke, Extrapolated from Nicotine Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling

    Article • International Journal of Environmental Research and Public Health, September 2010, MDPI AG

    Professor Hiroshi Yamazaki

  305. A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin

    Article • Xenobiotica, August 2010, Taylor & Francis

    Professor Hiroshi Yamazaki

  306. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population

    Article • European Journal of Clinical Pharmacology, August 2010, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  307. Biomonitoring of Urinary Cotinine Concentrations Associated with Plasma Levels of Nicotine Metabolites after Daily Cigarette Smoking in a Male Japanese Population

    Article • International Journal of Environmental Research and Public Health, July 2010, MDPI AG

    Professor Hiroshi Yamazaki

  308. Alprazolam as an In Vivo Probe for Studying Induction of CYP3A in Cynomolgus Monkeys

    Article • Drug Metabolism and Disposition, June 2010, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  309. Cynomolgus Monkey CYP2D44 Newly Identified in Liver, Metabolizes Bufuralol, and Dextromethorphan

    Article • Drug Metabolism and Disposition, May 2010, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  310. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles

    Article • British Journal of Clinical Pharmacology, May 2010, Wiley

    Professor Hiroshi Yamazaki

  311. Human Liver Microsomal Cytochrome P450 3A Enzymes Involved in Thalidomide 5-Hydroxylation and Formation of a Glutathione Conjugate

    Article • Chemical Research in Toxicology, May 2010, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki, Professor Norio Shibata

  312. Genetic Variants of CYP3A4 and CYP3A5 in Cynomolgus and Rhesus Macaques

    Article • Drug Metabolism and Disposition, February 2010, Elsevier

    Professor Hiroshi Yamazaki

  313. Comparison of Cytochrome P450 3A Enzymes in Cynomolgus Monkeys and Humans

    Article • Drug Metabolism and Pharmacokinetics, January 2010, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  314. Comparison of the Contributions of Cytochromes P450 3A4 and 3A5 in Drug Oxidation Rates and Substrate Inhibition

    Article • JOURNAL OF HEALTH SCIENCE, January 2010, Pharmaceutical Society of Japan

    Professor Hiroshi Yamazaki

  315. Identification and Characterization of CYP2C18 in the Cynomolgus Macaque (Macaca fascicularis)

    Article • Journal of Veterinary Medical Science, January 2010, Japanese Society of Veterinary Science

    Professor Hiroshi Yamazaki

  316. Effects of Histidine-Tag on Recombinant Human Cytochrome P450 3A5 Catalytic Activity in Reconstitution Systems

    Article • Drug Metabolism Letters, December 2009, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  317. Cloning, Expression, and Characterization of CYP3A43 in Cynomolgus Macaque (Macaca fascicularis)

    Article • Drug Metabolism Letters, December 2009, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  318. Approach for in Vivo Protein Binding of 5-n-Butyl-pyrazolo[1,5-a]pyrimidine Bioactivated in Chimeric Mice with Humanized Liver by Two-Dimensional Electrophoresis with Accelerator Mass Spectrometry

    Article • Chemical Research in Toxicology, November 2009, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  319. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes

    Article • Xenobiotica, October 2009, Taylor & Francis

    Professor Hiroshi Yamazaki

  320. Oxidation of Endobiotics Mediated by Xenobiotic-Metabolizing Forms of Human Cytochrome P450

    Article • Current Drug Metabolism, September 2009, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  321. Reverse Type I Binding Spectra of Human Cytochrome P450 1B1 Induced by Flavonoid, Stilbene, Pyrene, Naphthalene, Phenanthrene, and Biphenyl Derivatives That Inhibit Catalytic Activity: A Structure−Function Relationship Study

    Article • Chemical Research in Toxicology, June 2009, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  322. Two Novel CYP2D6*10 Haplotypes As Possible Causes of a Poor Metabolic Phenotype in Japanese

    Article • Drug Metabolism and Disposition, April 2009, Elsevier

    Professor Hiroshi Yamazaki

  323. Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding

    Article • Xenobiotica, March 2009, Taylor & Francis

    Professor Hiroshi Yamazaki

  324. Human Cytochrome P450 1A2 Involvement in the Formation of Reactive Metabolites from a Species-Specific Hepatotoxic Pyrazolopyrimidine Derivative, 5-n-Butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine

    Article • Chemical Research in Toxicology, January 2009, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  325. Bonitos with Low Content of Malodorous Trimethylamine as Palliative Care for Self-reported Japanese Trimethylaminuria Subjects

    Article • Drug Metabolism and Pharmacokinetics, January 2009, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  326. Cytochrome P450-depedent Drug Oxidation Activity of Liver Microsomes from Microminipigs, A Possible New Animal Model for Humans in Non-clinical Studies

    Article • Drug Metabolism and Pharmacokinetics, January 2009, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  327. Dose-dependent Effects of Cigarette Smoke on Blood Biomarkers in Healthy Japanese Volunteers: Observations from Smoking and Non-smoking

    Article • JOURNAL OF HEALTH SCIENCE, January 2009, Pharmaceutical Society of Japan

    Professor Hiroshi Yamazaki

  328. Genetic Polymorphisms of Glycine N-acyltransferase in Japanese Individuals

    Article • Drug Metabolism and Pharmacokinetics, January 2009, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  329. Identification and Characterization of CYP2B6 cDNA in Cynomolgus Macaques (Macaca fascicularis)

    Article • Journal of Veterinary Medical Science, January 2009, Japanese Society of Veterinary Science

    Professor Hiroshi Yamazaki

  330. Inter-individual Variation in Flavin-containing Monooxygenase 3 in Livers from Japanese: Correlation with Hepatic Transcription Factors

    Article • Drug Metabolism and Pharmacokinetics, January 2009, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  331. Pharmacokinetic Investigation of Increased Efficacy Against Malignant Gliomas of Carboplatin Combined With Hyperbaric Oxygenation

    Article • Neurologia medico-chirurgica, January 2009, Japan Neurosurgical Society

    Professor Hiroshi Yamazaki

  332. Increased distribution of carboplatin, an anti-cancer agent, to rat brains with the aid of hyperbaric oxygenation

    Article • Xenobiotica, November 2008, Taylor & Francis

    Professor Hiroshi Yamazaki

  333. Drug Interactions of Thalidomide with Midazolam and Cyclosporine A: Heterotropic Cooperativity of Human Cytochrome P450 3A5

    Article • Drug Metabolism and Disposition, October 2008, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  334. Interaction of Polycyclic Aromatic Hydrocarbons with Human Cytochrome P450 1B1 in Inhibiting Catalytic Activity

    Article • Chemical Research in Toxicology, October 2008, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  335. Increased transendothelial permeability of anti-cancer agent carboplatin with the aid of hyperbaric oxygenation

    Article • Xenobiotica, October 2008, Taylor & Francis

    Professor Hiroshi Yamazaki

  336. Effects of Enzyme Sources on Midazolam 1-Hydroxylation Activity Catalyzed by Recombinant Cytochrome P450 3A4 in Combination with NADPH-Cytochrome P450 Reductase

    Article • Drug Metabolism Letters, August 2008, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  337. Heterotropic Cooperativity in Oxidation Mediated by Cytochrome P450

    Article • Current Drug Metabolism, June 2008, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  338. Human Cytochrome P450 2A13 Efficiently Metabolizes Chemicals in Air Pollutants: Naphthalene, Styrene, and Toluene

    Article • Chemical Research in Toxicology, February 2008, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  339. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population

    Article • British Journal of Clinical Pharmacology, January 2008, Wiley

    Professor Hiroshi Yamazaki

  340. Comparison of Kinetic Parameters for Drug Oxidation Rates and Substrate Inhibition Potential Mediated by Cytochrome P450 3A4 and 3A5

    Article • Current Drug Metabolism, January 2008, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  341. Complex Mechanism Underlying Transcriptional Control of the Haplotyped Flavin-containing Monooxygenase 3 (FMO3) Gene in Japanese: Different Regulation between Mutations in 5′-Upstream Distal Region and Common Element in Proximal Region

    Article • Drug Metabolism and Pharmacokinetics, January 2008, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  342. Individual Differences in Toxicological Response Caused by a Diversity of Chemicals: Observations in Japan

    Article • Chemical Research in Toxicology, January 2008, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  343. Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3)

    Article • Pharmacogenetics and Genomics, October 2007, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  344. Involvement of human cytochrome P450 2B6 in theω- and 4-hydroxylation of the anesthetic agent propofol

    Article • Xenobiotica, July 2007, Taylor & Francis

    Professor Hiroshi Yamazaki

  345. Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes

    Article • Drug Metabolism and Disposition, June 2007, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  346. Genetic Polymorphism of the Flavin-Containing Monooxygenase 3 (FMO3) Associated with Trimethylaminuria (Fish Odor Syndrome): Observations from Japanese Patients

    Article • Current Drug Metabolism, June 2007, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  347. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes

    Article • Biochemical Pharmacology, June 2007, Elsevier

    Professor Hiroshi Yamazaki

  348. Pharmacokinetics of Antifungal Agent Micafungin in Critically Ill Patients Receiving Continuous Hemodialysis Filtration

    Article • YAKUGAKU ZASSHI, May 2007, Pharmaceutical Society of Japan

    Professor Hiroshi Yamazaki

  349. Different Mechanisms for Inhibition of Human Cytochromes P450 1A1, 1A2, and 1B1 by Polycyclic Aromatic Inhibitors

    Article • Chemical Research in Toxicology, February 2007, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  350. Transient trimethylaminuria related to menstruation

    Article • BMC Medical Genetics, January 2007, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  351. Effects of Propofol Analogs on Glucuronidation of Propofol, an Anesthetic Drug, by Human Liver Microsomes

    Article • Drug Metabolism Letters, January 2007, Bentham Science Publishers

    Professor Hiroshi Yamazaki

  352. Genetic Polymorphism of Bile acid CoA: Amino acid N-acyltransferase in Japanese Individuals

    Article • Drug Metabolism and Pharmacokinetics, January 2007, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  353. Missense and Nonsense Mutations of the Flavin-containing Monooxygenase 3 Gene in a Japanese Cohort

    Article • Drug Metabolism and Pharmacokinetics, January 2007, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  354. Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population

    Article • Molecular Genetics and Metabolism, January 2007, Elsevier

    Professor Hiroshi Yamazaki

  355. Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on N- and S-Oxygenation Activities

    Article • Drug Metabolism and Disposition, December 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  356. CYP2A13 expressed in human bladder metabolically activates 4‐aminobiphenyl

    Article • International Journal of Cancer, October 2006, Wiley

    Professor Hiroshi Yamazaki

  357. Rat Cytochrome P450 2C11 in Liver Microsomes Involved in Oxidation of Anesthetic Agent Propofol and Deactivated by Prior Treatment with Propofol

    Article • Drug Metabolism and Disposition, August 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  358. Prediction ofin vivodrug clearance fromin vitrodata. II: Potential inter-ethnic differences

    Article • Xenobiotica, June 2006, Taylor & Francis

    Professor Hiroshi Yamazaki

  359. Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans

    Article • Xenobiotica, April 2006, Taylor & Francis

    Professor Hiroshi Yamazaki

  360. Activities of Rat Cytochrome P450 3A and 2C Isoforms are Increased In Vivo by Magnesium Sulfate as Evidenced by Enhanced Oxidation of Bupivacaine and Testosterone in Liver Microsomes

    Article • Drug Metabolism and Pharmacokinetics, January 2006, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  361. In vivo Evaluation of Coumarin and Nicotine as Probe Drugs to Predict the Metabolic Capacity of CYP2A6 Due to Genetic Polymorphism in Thais

    Article • Drug Metabolism and Pharmacokinetics, January 2006, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  362. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations

    Article • Xenobiotica, January 2006, Taylor & Francis

    Professor Hiroshi Yamazaki

  363. Three Novel Single Nucleotide Polymorphisms of the FMO3 Gene in a Japanese Population

    Article • Drug Metabolism and Pharmacokinetics, January 2006, Japanese Society for the Study of Xenobiotics

    Professor Hiroshi Yamazaki

  364. Mild trimethylaminuria observed in a Japanese cohort with liver damage

    Article • The American Journal of Medicine, July 2005, Elsevier

    Professor Hiroshi Yamazaki

  365. CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS

    Article • Drug Metabolism and Disposition, June 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  366. Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas

    Article • Carcinogenesis, June 2005, Oxford University Press (OUP)

    Professor Hiroshi Yamazaki

  367. Sexual behaviour and high risk human papillomavirus infections in Japanese women

    Article • Sexually Transmitted Infections, June 2005, BMJ

    Professor Hiroshi Yamazaki

  368. Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108

    Article • Mutation Research/Genetic Toxicology and Environmental Mutagenesis, March 2005, Elsevier

    Professor Hiroshi Yamazaki

  369. High prevalence of cytochrome P 450 2A6*1A alleles in a black African population of Ghana

    Article • European Journal of Clinical Pharmacology, January 2005, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  370. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers

    Article • Xenobiotica, January 2005, Taylor & Francis

    Professor Hiroshi Yamazaki

  371. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens

    Article • Mutation Research/Genetic Toxicology and Environmental Mutagenesis, August 2004, Elsevier

    Professor Hiroshi Yamazaki

  372. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers

    Article • Carcinogenesis, June 2004, Oxford University Press (OUP)

    Professor Hiroshi Yamazaki

  373. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients

    Article • Life Sciences, April 2004, Elsevier

    Professor Hiroshi Yamazaki

  374. Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes

    Article • Biochemical Pharmacology, April 2004, Elsevier

    Professor Hiroshi Yamazaki

  375. Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene

    Article • Molecular Pharmacology, January 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  376. Effects of cytochrome b5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7

    Article • Biochemical Pharmacology, December 2003, Elsevier

    Professor Hiroshi Yamazaki

  377. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)

    Article • Pharmacogenetics, November 2003, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  378. Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes

    Article • Xenobiotica, January 2003, Taylor & Francis

    Professor Hiroshi Yamazaki

  379. A population phenotyping study of three drug‐metabolizing enzymes in Kyushu, Japan, with use of the caffeine test

    Article • Clinical Pharmacology & Therapeutics, August 2002, Wiley

    Professor Hiroshi Yamazaki

  380. Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay

    Article • Mutation Research/Genetic Toxicology and Environmental Mutagenesis, August 2002, Elsevier

    Professor Hiroshi Yamazaki

  381. Hepatocyte Nuclear Factor-1α Is a Causal Factor Responsible for Interindividual Differences in the Expression of UDP-Glucuronosyltransferase 2B7 mRNA in Human Livers

    Article • Drug Metabolism and Disposition, June 2002, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  382. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur

    Article • Pharmacogenetics, June 2002, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  383. Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes

    Article • Biochemical Pharmacology, June 2002, Elsevier

    Professor Hiroshi Yamazaki

  384. Evaluation of Approach to Predict the Contribution of Multiple Cytochrome P450s in Drug Metabolism Using Relative Activity Factor: Effects of the Differences in Expression Levels of NADPH–Cytochrome P450 Reductase and Cytochrome b5 in the Expression Sy...

    Article • Journal of Pharmaceutical Sciences, April 2002, Elsevier

    Professor Hiroshi Yamazaki

  385. Roles of NADPH-P450 Reductase and Apo- and Holo-Cytochrome b5 on Xenobiotic Oxidations Catalyzed by 12 Recombinant Human Cytochrome P450s Expressed in Membranes of Escherichia coli

    Article • Protein Expression and Purification, April 2002, Elsevier

    Professor Hiroshi Yamazaki

  386. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females

    Article • Pharmacogenetics, April 2002, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  387. Formation of a Novel Quinone Epoxide Metabolite of Troglitazone with Cytotoxic to HepG2 Cells

    Article • Drug Metabolism and Disposition, February 2002, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Professor Hiroshi Yamazaki

  388. P450 and carcinogenesis.

    Article • Folia Pharmacologica Japonica, January 2002, Japanese Pharmacological Society

    Professor Hiroshi Yamazaki

  389. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells

    Article • Life Sciences, December 2001, Elsevier

    Professor Hiroshi Yamazaki

  390. Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay

    Article • Mutation Research/Genetic Toxicology and Environmental Mutagenesis, October 2001, Elsevier

    Professor Hiroshi Yamazaki

  391. Stimulation of Cytochrome P450 Reactions by Apo-cytochromeb 5

    Article • Journal of Biological Chemistry, August 2001, Elsevier

    Professor Hiroshi Yamazaki

  392. Nicotine metabolism and CYP2A6 allele frequencies in Koreans

    Article • Pharmacogenetics, June 2001, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  393. Characterization of (??)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6

    Article • Pharmacogenetics, March 2001, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  394. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport

    Article • European Journal of Pharmaceutical Sciences, February 2001, Elsevier

    Professor Hiroshi Yamazaki

  395. Cooperativity ofα-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human

    Article • Xenobiotica, January 2001, Taylor & Francis

    Professor Hiroshi Yamazaki

  396. Article • Pharmaceutical Research, January 2001, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  397. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans

    Article • Clinical Pharmacology & Therapeutics, January 2001, Wiley

    Professor Hiroshi Yamazaki

  398. Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1

    Article • Mutation Research/Genetic Toxicology and Environmental Mutagenesis, December 2000, Elsevier

    Professor Hiroshi Yamazaki

  399. Characterization of liver microsomal 7-ethoxycoumarin O -deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene

    Article • Archives of Toxicology, September 2000, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  400. A new PCR-based assay amplifies the E6–E7 genes of most mucosal human papillomaviruses (HPV)

    Article • Virus Research, April 2000, Elsevier

    Professor Hiroshi Yamazaki

  401. Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions

    Article • British Journal of Clinical Pharmacology, March 2000, Wiley

    Professor Hiroshi Yamazaki

  402. Article • Pharmaceutical Research, January 2000, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  403. Phospholipase D Activity of Cytochrome P450 in Human Liver Endoplasmic Reticulum

    Article • Archives of Biochemistry and Biophysics, July 1999, Elsevier

    Professor Hiroshi Yamazaki

  404. Role of human N-acetyltransferases, NAT1 or NAT2, in genotoxicity of nitroarenes and aromatic amines in Salmonella typhimurium NM6001 and NM6002

    Article • Carcinogenesis, June 1999, Oxford University Press (OUP)

    Professor Hiroshi Yamazaki

  405. Molecular Cloning of a Novel Human Collectin from Liver (CL-L1)

    Article • Journal of Biological Chemistry, May 1999, Elsevier

    Professor Hiroshi Yamazaki

  406. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes

    Article • Archives of Toxicology, April 1999, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  407. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes

    Article • Xenobiotica, January 1999, Taylor & Francis

    Professor Hiroshi Yamazaki

  408. Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes

    Article • Journal of Chromatography B Biomedical Sciences and Applications, January 1999, Elsevier

    Professor Hiroshi Yamazaki

  409. Selectivity of Polycyclic Inhibitors for Human Cytochrome P450s 1A1, 1A2, and 1B1

    Article • Chemical Research in Toxicology, August 1998, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  410. Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and Its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes

    Article • Biochemical Pharmacology, July 1998, Elsevier

    Professor Hiroshi Yamazaki

  411. Activation and detoxication of aflatoxin B1

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, June 1998, Elsevier

    Professor Hiroshi Yamazaki

  412. Roles of Cytochromes P450 1A2 and 3A4 in the Oxidation of Estradiol and Estrone in Human Liver Microsomes

    Article • Chemical Research in Toxicology, May 1998, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  413. Linkage between the distribution of mutations in theCYP2C18andCYP2C19genes in the Japanese and Caucasian

    Article • Xenobiotica, January 1998, Taylor & Francis

    Professor Hiroshi Yamazaki

  414. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes

    Article • Xenobiotica, January 1998, Taylor & Francis

    Professor Hiroshi Yamazaki

  415. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers

    Article • Biochemical Pharmacology, December 1997, Elsevier

    Professor Hiroshi Yamazaki

  416. Progesterone and Testosterone Hydroxylation by Cytochromes P450 2C19, 2C9, and 3A4 in Human Liver Microsomes

    Article • Archives of Biochemistry and Biophysics, October 1997, Elsevier

    Professor Hiroshi Yamazaki

  417. Aflatoxin B1 8,9-Epoxide Hydrolysis in the Presence of Rat and Human Epoxide Hydrolase

    Article • Chemical Research in Toxicology, June 1997, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  418. Reconstitution of Recombinant Cytochrome P450 2C10(2C9) and Comparison with Cytochrome P450 3A4 and Other Forms: Effects of Cytochrome P450–P450 and Cytochrome P450–b5Interactions

    Article • Archives of Biochemistry and Biophysics, June 1997, Elsevier

    Professor Hiroshi Yamazaki

  419. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans

    Article • Archives of Toxicology, April 1997, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  420. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4???-hydroxylation activities in livers of Japanese and Caucasian populations

    Article • Pharmacogenetics, April 1997, Wolters Kluwer Health

    Professor Hiroshi Yamazaki

  421. Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4

    Article • Journal of Biological Chemistry, November 1996, Elsevier

    Professor Hiroshi Yamazaki

  422. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes

    Article • Biochemical Pharmacology, July 1996, Elsevier

    Professor Hiroshi Yamazaki

  423. High Rates of Substrate Hydroxylation by Human Cytochrome P450 3A4 in Reconstituted Membranous Vesicles: Influence of Membrane Charge

    Article • Biochemical and Biophysical Research Communications, April 1996, Elsevier

    Professor Hiroshi Yamazaki

  424. Recombinant Human Cytochrome P450 1A2 and an N-Terminal-Truncated Form: Construction, Purification, Aggregation Properties, and Interactions with Flavodoxin, Ferredoxin, and NADPH-Cytochrome P450 Reductase

    Article • Archives of Biochemistry and Biophysics, March 1996, Elsevier

    Professor Hiroshi Yamazaki

  425. 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes

    Article • Biochemical Pharmacology, February 1996, Elsevier

    Professor Hiroshi Yamazaki

  426. A new Salmonella typhimurium NM5004 strain expressing rat glutathione S-transferase 5–5: use in detection of genotoxicity of dihaloalkanes using an SOS/umu test system

    Article • Carcinogenesis, January 1996, Oxford University Press (OUP)

    Professor Hiroshi Yamazaki

  427. Activation and Inactivation of Carcinogenic Dihaloalkanes and Other Compounds by Glutathione S-Transferase 5-5 in Salmonella typhimurium Tester Strain NM5004

    Article • Chemical Research in Toxicology, January 1996, American Chemical Society (ACS)

    Professor Hiroshi Yamazaki

  428. Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes

    Article • Archives of Biochemistry and Biophysics, January 1996, Elsevier

    Professor Hiroshi Yamazaki

  429. Mutagenic Activation of 3-Methoxy-4-aminoazobenzene by Mouse Renal Cytochrome-P450 CYP4B1: Cloning and Characterization of Mouse CYP4B1

    Article • Archives of Biochemistry and Biophysics, August 1995, Elsevier

    Professor Hiroshi Yamazaki

  430. Development of high sensitive umu test system: rapid detection of genotoxicity of promutagenic aromatic amines by Salmonella typhimurium strain NM2009 possessing high O-acetyltransferase activity

    Article • Mutation Research/Environmental Mutagenesis and Related Subjects, April 1995, Elsevier

    Professor Hiroshi Yamazaki

  431. Volume 317, Number 2 (1995), in the article "Expression of Cytochrome P450-3A5 in Escherichia-Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities," by Elizabeth M. J. Gillam, Zu...

    Article • Archives of Biochemistry and Biophysics, April 1995, Elsevier

    Professor Hiroshi Yamazaki

  432. Expression of Cytochrome-P450-3A5 in Escherichia Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities

    Article • Archives of Biochemistry and Biophysics, March 1995, Elsevier

    Professor Hiroshi Yamazaki

  433. Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7α- and coumarin 7-hydroxylations

    Article • Biochemical Pharmacology, October 1994, Elsevier

    Professor Hiroshi Yamazaki

  434. Fluorescencein situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1

    Article • The Japanese Journal of Human Genetics, September 1994, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  435. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes

    Article • Biochemical Pharmacology, June 1994, Elsevier

    Professor Hiroshi Yamazaki

  436. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes

    Article • Biochemical Pharmacology, February 1994, Elsevier

    Professor Hiroshi Yamazaki

  437. Rat pulmonary microsomal cytochrome P-450 enzymes involved in the activation of procarcinogens

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, December 1992, Elsevier

    Professor Hiroshi Yamazaki

  438. Use of a newly developed tester strain Salmonella typhimurium NM2009 for the study of metabolic activation of carcinogenic aromatic amines by rat liver microsomal cytochrome P-450 enzymes

    Article • Mutation Research/Environmental Mutagenesis and Related Subjects, October 1992, Elsevier

    Professor Hiroshi Yamazaki

  439. Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescencein situ hybridization

    Article • The Japanese Journal of Human Genetics, June 1992, Springer Science + Business Media

    Professor Hiroshi Yamazaki

  440. Cytochrome P-450 forms and its inducibility by PCB isomers in black-headed gulls and black-tailed gulls

    Article • Marine Pollution Bulletin, June 1992, Elsevier

    Professor Hiroshi Yamazaki

  441. The evaluation of genotoxic activities of disinfectants and their metabolites by umu test

    Article • Mutation Research Letters, November 1988, Elsevier

    Professor Hiroshi Yamazaki

  442. Mutagenicity of N-nitrosodiethanolamine in the Salmonella/microsome test

    Article • Mutation Research Letters, October 1987, Elsevier

    Professor Hiroshi Yamazaki

  443. Activation of carcinogenic N-nitrosopropylamines to mutagens by lung and pancreas S9 fractions from various animal species and man

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, May 1986, Elsevier

    Professor Hiroshi Yamazaki

  444. Genotoxicity of carcinogenic N-nitrosopropylamine derivatives in the hepatocyte primary culture/DNA-repair test

    Article • Mutation Research Letters, November 1985, Elsevier

    Professor Hiroshi Yamazaki

  445. Inhibitory effect of organic solvents on the mutagenicity of N-nitrosodialkylamines in Salmonella

    Article • Mutation Research Letters, April 1985, Elsevier

    Professor Hiroshi Yamazaki